| P/E (FY) | — | Sales (TTM) | $37,653 |
| Earnings (TTM) | -$9.8M | ROE | — |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $2.2M | Trading Days | 1535 |
| 52W High | 1.45 |
| 52W Low | 0.49 |
| % Off High | −65.72% |
| YTD | −36.28% | 1Y | −63.99% |
| 3Y | −99.57% | 5Y | −99.96% |
| Since incept. (ann.) | −70.91% |
| Ann. Volatility (1Y) | 70.14% | Ann. Volatility (3Y) | 121.52% |
| Sharpe (1Y) | −1.13 | Sharpe (3Y) | −0.86 |
| Max Drawdown (1Y) | −65.00% | Max Drawdown (3Y) | −99.76% |
| Beta (3Y, vs SPY) | 1.72 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| VCNX | VACCINEX, INC. | $2.2M | — |
| NXTS | Nexentis Technologies Inc. | $2.2M | — |
| ARTL | ARTELO BIOSCIENCES, INC. | $2.4M | — |
| MTNB | Matinas BioPharma Holdings, Inc. | $2.1M | — |
| AZTR | Azitra, Inc. | $2.1M | — |
| GRI | GRI Bio, Inc. | $2.5M | — |
| PKTX | ProtoKinetix, Inc. | $2.6M | — |
| BPTH | BIO-PATH HOLDINGS, INC. | $1.9M | — |
| DCOY | Decoy Therapeutics Inc. | $2.7M | — |
| ACUT | Accustem Sciences Inc. | $3.5M | — |
| HEPA | Hepion Pharmaceuticals, Inc. | $1.4M |
| ENSC | Ensysce Biosciences, Inc. | $3.8M | — |
